Business Strategy

A Phase IIb trial testing Cartesian’s autologous mRNA-engineered CAR-T therapy for the treatment of generalized myasthenia gravis (MG) met the primary endpoint.

Lilly paid $140m up front for an option to acquire Radionetics for $1bn within an undisclosed timeframe. The private firm is developing small molecule GPCR-targeted radiopharmaceuticals.

The Madrid-headquartered group could see its finances transformed with a sale of its third party manufacturing services which have blossomed through its partnership with Moderna.

Deal Snapshot: Merck said it would pay potentially more than $1.6bn for an exclusive global license for opevesostat for metastatic castrate-resistant prostate cancer.

The green light from the European Commission for Ixchiq marks the third regulatory approval for the world’s first vaccine for chikungunya and extends the French biotech's lead over rival Bavarian Nordic.

Public Company Edition: Alumis grosses $250m after it planned to raise up to $317.7m in its IPO. Also, Zealand adds $1bn in a post-data offering, Tectonic and Eliem close $130.7m and $120m private placements to support recent mergers, and Ginkgo cuts 35% of its workforce.

On the back of a “truly one in a million” case, Ashibio has revived research into Gilead's discontinued asset andecaliximab after it showed promise in the ultra-rare musculoskeletal condition FOP.

Ensho Therapeutics is raising series A cash to develop Phase II-ready NSHO-101 (EA1080), a third oral ɑ4β7 integrin inhibitor attempting to take on Takeda’s blockbuster injectable Entyvio.

Phase IIb data for Auxora in an acute pancreatitis subpopulation is expected to set up the CRAC channel inhibitor for Phase III in that indication while suggesting positive read-through for AKI.

2seventy bio sold full rights to a hemophilia A program and in vivo gene editing technology to partner Novo Nordisk.

The respiratory specialist is set to hit the ground running with Ohtuvayre, the first COPD inhaled product with a novel mechanism of action to be approved in over two decades.

Arrowhead’s in-house, late-stage cardiovascular disease programs will center on triglyceride-lowering plozasiran while it seeks a partner to fund Phase III for cholesterol-reducing zodasiran.